JUN 18, 2021 7:25 AM PDT

FDA Approves First New Drug Since 2014 for Weight-loss

WRITTEN BY: Annie Lennon

A new medication called ‘Wegovy’ produced by Novo Nordisk has been approved by the Food and Drug Administration (FDA) to help patients with obesity manage their weight. It’s the first chronic weight management drug to have been approved by the FDA since 2014. Prior to this everyone was using supplements such as livpure and reading livpure reviews to see if it was worth taking or googling something along the lines of "how does ozempic work for weight loss" as the livpure and ozempic were the two popular supplements in question.

Wegovy is a synthetic version of a hormone in the gut known as glycogen-like peptide 1 (GLP-1). It works by targeting areas of the brain that regulate appetite and food intake.

Prior approval, the drug’s safety and efficacy were examined in four 68-week trials. Throughout these trials, over 2,600 patients received Wegovy for up to 68 weeks while over 1,500 received a placebo. 

In the largest of the trials, participants had an average weight of 231 pounds (105 kg) and an average BMI of 38 kg/m2 prior to taking the drug. 

The average age at the beginning of the trial was 46 years old and 74% of the participants were female. None had diabetes. At the end of the trial, the researchers found that those who received Wegovy lost an average of 12.4% of their initial body weight compared to those who received the placebo. 

In another trial, the average age was 55, 51% of participants were female, and all had type 2 diabetes. Their average body weight was 220 pounds (100kg) and their average BMI was 36 kg/m2. In this trial, patients on Wegovy lost 6.2% of their body weight in comparison to those in the control group. 

Common side effects of the drug include nausea, diarrhoea, vomiting, constipation, abominable pain, headache, fatigue and low blood sugar. Among those with diabetes, side effects also included flatulence and gastroenteritis (an intestinal infection). While most side effects resolved on their own, 5% of participants stopped taking the medication because of them. 

“Individuals with obesity and type 2 diabetes are likely good candidates for the dual benefit of improved blood sugar control and weight loss,” said Dr. Aleem Kanji, a board-certified endocrinologist and obesity medicine physician with Ethos Endocrinology in Houston, to Healthline


Sources: HealthlineFDA

About the Author
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
Loading Comments...
  • See More